| Literature DB >> 34642392 |
Toshihide Nishimura1,2, Kiyonaga Fujii3,4,5, Haruhiko Nakamura3,4, Saeko Naruki6, Hiroki Sakai4, Hiroyuki Kimura4, Tomoyuki Miyazawa4, Masayuki Takagi6, Naoki Furuya7, Gyorgy Marko-Varga8, Harubumi Kato9,10, Hisashi Saji4.
Abstract
No therapeutic targets have been identified for lung squamous cell cancer (SqCC) which is the second most prevalent lung cancer because its molecular profiles remain unclear. This study aimed to unveil disease-related protein networks by proteomic and bioinformatic assessment of laser-microdissected cancerous cells from seven SqCCs compared with eight representative lung adenocarcinomas. We identified three network modules significant to lung SqCC using weighted gene co-expression network analysis. One module was intrinsically annotated to keratinization and cell proliferation of SqCC, accompanied by hypoxia-induced aerobic glycolysis, in which key regulators were activated (HIF1A, ROCK2, EFNA1-5) and highly suppressed (KMT2D). The other two modules were significant for translational initiation, nonsense-mediated mRNA decay, inhibited cell death, and interestingly, eIF2 signaling, in which key regulators, MYC and MLXIPL, were highly activated. Another key regulator LARP1, the master regulator in cap-dependent translation, was highly suppressed although upregulations were observed for hub proteins including EIF3F and LARP1 targeted ribosomal proteins, among which PS25 is the key ribosomal protein in IRES-dependent translation. Our results suggest an underlying progression mechanism largely caused by switching to the cap-independent, IRES-dependent translation of mRNA subsets encoding oncogenic proteins. Our findings may help to develop therapeutic strategies to improve patient outcomes.Entities:
Mesh:
Year: 2021 PMID: 34642392 PMCID: PMC8511190 DOI: 10.1038/s41598-021-99695-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Clinicopathological information.
| Sample no. | Age (years) | Sex | Histological type | Surgical method | Location | Tumor size on CT (mm) | Clinical TNM classification | Clinical stage | Smoking index (BI) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| c-T | c-N | c-M | |||||||||||
| SqCC_T60 | 76 | M | SqCC | Radical lobectomy | LS6 | 21 | cT1b | cN0 | cM0 | cIA | 4400 | Unknown | |
| SqCC_T62 | 74 | M | SqCC | Radical lobectomy | LS6 | 20 | cT1a | cN0 | cM0 | cIA | 1000 | Unknown | |
| SqCC_T63 | 56 | M | SqCC | Limited resection | LS1 + 2 | 15 | cT1a | cN0 | cM0 | cIA | 720 | Unknown | |
| SqCC_T64 | 65 | M | SqCC | Radical lobectomy | RS4 | 19 | cT1a | cN0 | cM0 | cIA | 900 | Unknown | |
| SqCC_T66 | 60 | M | SqCC | Radical lobectomy | LS6 | 21 | cT1b | cN0 | cM0 | cIA | 800 | Unknown | |
| SqCC_T67 | 63 | F | SqCC | Radical lobectomy | RS3 | 12 | cT1a | cN0 | cM0 | cIA | 840 | Unknown | |
| SqCC_T68 | 77 | M | SqCC | Radical lobectomy | LS4 | 20 | cT1a | cN0 | cM0 | cIA | 500 | Unknown | |
| M (85.7%) / F (14.3%) | |||||||||||||
| Average ± SD | 67.3 ± 8.4 | 18.3 ± 3.5 | |||||||||||
| PPA_T10 | 46 | F | PPA (AD) | Radical lobectomy | LS10 | 26 | cT1b | cN0 | cM0 | cIA | 0 | Positive | exon 21 L858R, exon20 T790M |
| PPA_T11 | 61 | F | PPA (AD) | Radical lobectomy | LS9 | 16 | cT1a | cN0 | cM0 | cIA | 0 | Positive | exon19 deletion E746-A751del |
| PPA_T12 | 71 | F | PPA (AD) | Radical lobectomy | RS3 | 26 | cT1b | cN0 | cM0 | cIA | 0 | Positive | exon19 deletion E746-A751del, S752I (TCT → ATT) |
| PPA_T13 | 73 | F | PPA (AD) | Radical lobectomy | LS1 + 2 LS9 | 40, 22 | T2a, T1b | cN0 | cM0 | cIB | 0 | Negative | |
| PPA_T14 | 63 | F | PPA (AD) | Radical lobectomy | RS8 | 13 | cT1a | cN0 | cM0 | cIA | 0 | Positive | exon 21 L858R |
| PPA_T15 | 68 | F | PPA (AD) | Radical lobectomy | RS2 | 26 | cT1b | cN0 | cM0 | cIA | 0 | Positive | L858R |
| PPA_T16 | 73 | M | PPA (AD) | Radical lobectomy | RS4 | 10 | cT1a | cN0 | cM0 | cIA | 1060 | Negative | |
| PPA_T17 | 57 | F | PPA (AD) | Radical lobectomy | RS1 | 27 | cT1b | cN0 | cM0 | cIA | 0 | Negative | |
| M (12.5%)/F (87.5%) | |||||||||||||
| Average ± SD | 64.0 ± 9.3 | 18.0 ± 9.9 | |||||||||||
| 0.244 | 0.234 | 0.018 | |||||||||||
SqCC squamous cell carcinoma, PPA papillary predominant adenocarcinoma, AD adenocarcinoma, BI Brinkmann Index.
Figure 1Venn map and hierarchical clustering of the identified proteins. (A) Venn map of the identified proteins. (B) Gene ontology (GO) analysis of the identified proteins for SqCC and PPA. (1) Biological process. 1, developmental process (GO:0032502); 2, multicellular organismal process (GO:0032501); 3, cellular process (GO:0009987); 4, reproduction (GO:0000003); 5, localization (GO:0051179); 6, reproductive process (GO:0022414); 7, multi-organism process (GO:0051704); 8, biological adhesion (GO:0022610); 9, immune system process (GO:0002376); 10, biological regulation (GO:0065007); 11, growth (GO:0040007); 12, signalling (GO:0023052); 13, metabolic process (GO:0008152); 14, interspecies interaction between organisms (GO:0044419); 15, response to stimulus (GO:0050896); 16, pigmentation (GO:0043473); 17, biological phase (GO:0044848); 18, behavior (GO:0007610); 19, locomotion (GO:0040011). (2) Protein class. 1, extracellular matrix protein (PC00102); 2, cytoskeletal protein (PC00085); 3, transporter (PC00227); 4, scaffold/adaptor protein (PC00226); 5, cell adhesion molecule (PC00069); 6, nucleic acid metabolism protein (PC00171); 7, intercellular signal molecule (PC00207); 8, protein-binding activity modulator (PC00095); 9, viral or transposable element protein (PC00237); 10, calcium-binding protein (PC00060); 11, gene-specific transcriptional regulator (PC00264); 12, defense/immunity protein (PC00090); 13, translational protein (PC00263); 14, metabolite interconversion enzyme (PC00262); 15, protein-modifying enzyme (PC00260); 16, chromatin/chromatin-binding, or -regulatory protein (PC00077); 17, transfer/carrier protein (PC00219); 18, membrane traffic protein (PC00150); 19, chaperone (PC00072); 20, cell junction protein (PC00070); 21, structural protein (PC00211); 22, storage protein (PC00210); 23, transmembrane signal receptor (PC00197).
Figure 2Protein network modules identified by weighted gene co-expression network analysis (WGCNA). (A) Protein dendrogram obtained by clustering the dissimilarity based on consensus topological overlap with the corresponding module. Colored rows correspond to the 30 modules identified. (B) Heatmap of semiquantitative expressions of module eigen proteins with samples. (C) Pairwise correlations between the modules in the heatmap of eigen proteins in module membership.
Figure 3Data-driven protein co-expression networks and pathway enrichment results obtained for the lung SqCC trait. (A) The co-expression networks of respective modules: (1) WM26, (2) WM27, and (3) WM28 modules. Circle nodes in blue gradation and dotted red represent eigen proteins and/or hub proteins, respectively, for each module, and circle nodes in red gradation also indicate key proteins in the network modules. Dashed circles in black denote subnetworks and protein groups. (B) Among pathways enriched for the protein core networks obtained for biological process (GO) and Reactome pathways, the top 20 pathways are presented in the order of significance by the q-value. The dashed circles denote subnetworks and protein groups.
Figure 4Multivariate correlation analysis for the spectral counting-based expression of 89 eigen proteins and/or hub proteins and other key proteins expressed among all the modules identified for both the SqCC and PPA traits. Clusters are denoted by a, b, c, d, and e. Eigen proteins in the WGCNA network modules significant for SqCC or PPA are denoted in red or blue letters, respectively; the hub proteins are also indicated by red or blue-filled circles, respectively.
Representative master regulators predicted to be activated or inhibited (|z-value|> 2.0) and upregulated (1.5 < z-value < 2.0) are summarized for the three WGCNA modules significant to lung SqCC (network bias-corrected p-value < 0.005), in which top annotations on canonical pathways, diseases or functions, and downstream regulatory effects are also provided.
| Module ID (color) | Causal networks | Canonical pathways | Diseases or functions | Downstream regulatory effects | |||||
|---|---|---|---|---|---|---|---|---|---|
| Master regulators | z-score | Top annotations (z-value) | Top annotations | (z-value) | Top annotation | Consistency | |||
| WM26 (blue) | 3.638 | Glucocorticoid receptor signaling | 5.01E−24 | Keratinization of epidermis | 2.46E−52 | Cell proliferation of squamous cell carcinoma cell lines | 3.795 | ||
| 2.646 | HIPPO signaling (− 1) | 1.78E−04 | |||||||
| 2.449 | Purine ribonucleosides degradation to ribose-1-phosphate | 2.95E−04 | |||||||
| 2.236 | Cell cycle: G2/M DNA damage checkpoint regulation | 5.62E−04 | |||||||
| Desmoplakin, | 2 | ERK5 signaling | 1.74E−03 | ||||||
| 2 | p53 signaling | 4.17E−03 | |||||||
| Tumor protein 63 ( | 1.897 | IGF-1 signaling | 4.90E−03 | ||||||
| Max dimerization protein 1 ( | − 2.132 | ||||||||
| − 2.828 | |||||||||
| − 2.828 | |||||||||
| WM27 (darkturquoise) | Zinc finger E-box-binding homeobox ( | 2.714 | EIF2 signaling | 1.26E−07 | Initiation of translation of protein | 9.92E−09 | N/A | ||
| Carbohydrate-responsive element-binding protein ( | 2 | mTOR signaling | 7.59E−05 | Nonsense-mediated mRNA decay | 1.22E−07 | ||||
| 2 | Regulation of eIF4 and p70S6K Signaling | 7.76E−04 | Metabolism of protein | 1.12E−05 | (− 0.436) | ||||
| Baculoviral IAP repeat-containing protein ( | 1897 | Remodeling of Epithelial Adherens Junctions | 2.51E−03 | ||||||
| 1.89 | |||||||||
| 1.633 | |||||||||
| Rapamycin-insensitive companion of mTOR ( | − 2 | ||||||||
| 5-Fluorouracil(5-FU), chemical drug intervention | − 2 | ||||||||
| La-related protein 1 ( | − 2.24 | ||||||||
| − 2.714 | |||||||||
| WM28 (orange) | 4 | EIF2 signaling | 2.51E−35 | Initiation of translation of protein | 5.31E−39 | Cell death of osteosarcoma cells | 8.132 | ||
| 3.873 | Regulation of eIF4 and p70S6K signaling | 2.00E−20 | Nonsense-mediated mRNA decay | 1.31E−35 | |||||
| 3.742 | mTOR signaling | 3.16E−19 | Translation of protein | 4.18E−31 | |||||
| 2.449 | HIF1α signaling | 1.78E−02 | Metabolism of protein | 1.81E−21 | (− 1.72) | ||||
| − 2.138 | Insulin secretion signaling pathway | 2.51E−02 | Cell death of osteosarcoma cells | 5.88E−13 | (− 2.828) | ||||
| CD 437, chemical drug intervention | − 2.236 | Translation of mRNA | 2.65E−11 | ||||||
| ST1926, chemical drug intervention | − 2.449 | Cell death of tumor cells | 2.28E−10 | (− 2.53) | |||||
| − 3 | Cell death of cancer cells | 1.09E−09 | (− 2.333) | ||||||
| Sirolimus (Rapamycin), chemical drug intervention | − 3.464 | ||||||||
| La-related protein 1 ( | − 3.873 | ||||||||
Figure 5The integrative networks of representative master and participating regulators predicted for the WM26 module.
Figure 6The integrative networks of representative master and participating regulators predicted for the WM27 and WM28 modules, together with chemical drug interventions (CD 437, ST1926, and sirolimus [rapamycin]).